90% was never realistic. If you thought that number was going to stick, then shame on you for having completely unrealistic expectations and clearly not doing your homework. That was in a 7 patient open study and you are comparing it to a 40 patient blinded study. The results today are better than anything that exists. Comparing to the 7 patient study would lead one to believe the results aren't good. However, when compared to current alternatives, which is all that matters, these results are exceptional. If STRIDE results are similar, then you can expect this stock to soar. You can fully expect a bit more of a run up prior to STRIDE as well.
took you off ignore since I probably won't be on this board much anymore. yeah I know one person who cares about my opinion: ME! what I would like is someone to change that opinion with some real facts, instead of your paranoid ramblings. hey, good luck... this may have a chance at approval, and so you could probably double your money from here if that's the case. sincerely.
This is how it's done:
Bogus posts here from Adam Fuerstien/ Wild Bill and his boys timed with huge bid stack retractions like 10,000/200 10:26EST strobed AND combined with naked shorting at a lower bid to bring the price down.... and then strobing a high bid with retractions like 5,300/100 strobed at 10:56EST after Bill's post for minutes to lock the move down like. Repeat.
Folks call me crazy, and I just report the facts. Down twelve cents at this print.
Open label news in the future shuts down these schemes forever.
good luck, I hope you're right but the company's track record tells me that this PR is their best attempt at a pump, and it's not amazing to me. If I need a PHD to understand it, then at the least they are not communicating well. but if it's really so great why is pps down? don't give me any "manipulation" nonsense. big money buys when they see a winner. if this were really a miracle arthritis drug, the multi-billion dollar long potential would far outweigh any "short manipulation" profits
For the last time.... there are maybe 20 people who read this message board. If you honestly think that one person can change the stock price in here by posting something... oh yea you're crazy. Never mind.
Queue the FUNK-hyphenated words, crazy rants, and conspiracies.
can u please drive down a major highway going the wrong way aiming for one of those big digital highway signs not coming headlights? Funkmiester SS man . how is ADOLF your son? PLEASE PLEASE get dead already . MR SS funkmiester and RI66 these names makes US ill knowing you are still breathing so please stop,Thanks
results show that the drug works. I think this will move forward. Not amazing, I know some people claim that. Maybe it's amazing compared to there being no other good treatments for the worst arthritis pain levels but... when you say 64% improvement that just doesn't sound exciting. They were talking about 90% improvement, cartilage regeneration, almost a miracle cure. 64% just sounds disappointing to A LAYMAN LIKE MYSELF, and that's the common investor. if you are far more educated on the subject and know better, buy here knowing you will succeed in the end. For now I'm out. If they show any of the miracle stats like cartilage regeneration, i'll buy back in, even at twice the current market cap... until then this is *yawn* probably a minor success, with only one drug to hang all your hopes on and inevitable bad news for optina which they are hanging over your head for some reason.
It's not a bust, but the market response should tell you something, even if the numbers don#$%$ better than what is currrently available, so that should be good enough. I would have preferred to hear specific comparative statements directly from the clinicians involved, as we had with SPRING. Good - yes. Great - not convinced.
STRIDE is the only trial that counts towards approval. There are 8 times as many patients dosed with Ampion compared to STRIDE/Phase II. We dropped from 90% to 65% in going from N=7 to N=20. There isn't any evidence we would do *better* than 65% with even a larger population.
Me too...closest out my AMPE position...going to NWBO too! GLTA.( thx for the tip on NWBO...looks real promising!)
I am quite familar with the WOMAC scale. I also know alternatives and statistics. Hardly amazing. The numbers are quite clear. The ambiguities are all part of the high standard deviation.
This is the same argument made with the first 7 patients. It is completely incorrect to assume similar response with a larger population. The 20 patients here in the Ampion arm is also small, but provides a better outlook as to the true value of the drug.
bill isn't this actually a very strong result, significantly better than what is approved at the moment, the strong results for the 7 patients could be a fluke but a 40 patient blind study with these results suggests we are on to something.
SORRY BILL - YOU ARE ABSOLUTELY 100% WRONG . . . when one realizes the REAL efficacy expressed in the Responder Rate numbers, the outcome is exactly AMAZING.
You are being misguided by the wrong numbers and should read up on what the American College Of Arthritis recommends to overcome the ambiguities and inaccuracy of the WOMAC scale.
A paper addressing this subject was published in 2003 and is very clear.
Sentiment: Strong Buy
I could run a statistical estimate based with means, sd, and N, but the sd is very high. Actually, it's worse, since it should be arm-dependent, hence estimating the outcome of 160 patients from the data of just 20. If the p value were less than 0.001 (highly significant) I would feel much more comfortable. 65% sounds like a lot, but we need to remember that 40% is Minimal Clinical Effectiveness. So, it's just twice minimal effectiveness. Still, that's better than all HA formulations, which I believe to be the primary competing alternative for KL3 and KL4.
Seeing some stronger reaction in the market would be reassuring. It will be interesting to see how we end the day.
Looks like we got both! And looks like Wall Street could care less at N=40...Hopefully Big Pharma cares more about this data...
the womac score at 2 weeks for the 40 patient study was 69% versus a 79% responder rate
the responder rate is far more accurate and explained in more detail in a the journal of the college of american arthriitis published in 2003
today's results are being misunderstood by the street but that is not surprising
big pharma understands the significance of responder rates over womac scale very well and will be motivated to step up their efforts to license ampion sooner than later
with data this strong, it is to risky to wait any longer so don't be surprised if big pharma liciensing talks heat up very quickly
Sentiment: Strong Buy